Drug intelligence / Profile preview

pkf-275-055

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

PKF-275-055 is a **novel, selective inhibitor of dipeptidyl peptidase-4 (DPP-IV)**, classified as a vildagliptin analog. It has been shown in preclinical studies to improve glycemic control, enhance pancreatic β-cell mass, and reduce inflammation in animal models of diabetes. Its mechanism of action is related to inhibiting the DPP-IV enzyme, which regulates incretin hormones important for insulin secretion. PKF-275-055 has also demonstrated anti-inflammatory effects and has been explored for its potential to modulate the gut microbiota and improve metabolic markers, showing some distinct effects compared to metformin in animal studies[1][3][6].

Other names: PKF-275-055PKF275-055PKF 275-055

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on pkf-275-055.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pkf-275-055.

Explore the full profile